Janssen Diagnostics Inc. | Date: 2015-09-16
The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers.
News Article | May 1, 2017
— According to Stratistics MRC, the Global Circulating Tumor Cells Market is accounted for $4.41 billion in 2015 and is expected to reach $17.96 billion by 2022 growing at a CAGR of 19.2 % from 2015 to 2022. The rising demand for high Benefit-Cost Ratio (BCR) associated with CTCs prognostic technology is the major factor boosting the market growth. Furthermore, advancements in biomedical imaging and bioengineering technology are some of the key factors driving the market. However, high cost associated with the diagnosing and reluctance among people towards adopting highly developed prognostic technologies inhibit the market growth. The recent trends in global Circulating Tumor Cells are strengthening distribution network of CTCs prognostic technologies in emerging economies and the technical advancement of CTCs-based customized medicines. Tumor cell detection is the foremost product segment primarily due to the advantages related with therapeutic monitoring and high procedure prices. North America region is expected to witness highest growth rate during the forecast period due to increasing demand in number of research projects. In addition, the U.S. Government also supports research by funding various institutes, which grant research funds. Some of the key players in the market include Adnagen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept Inc., Biofluidica, Canopus Biosciences, CellTraffix Inc., Clearbridge BioMedics, Creatv Microtech Inc., Cynvenio Biosystems Inc. , Epic Biosciences, Fluxion Biosciences., Greiner Bio-One GmbH, Ikonisys Inc., IV Diagnostics Inc., Janssen Diagnostics, Miltenyi Biotech and Nanostring Technologies Inc. Regions Covered: North America US Canada Mexico Europe Germany France Italy UK Spain Rest of Europe Asia Pacific Japan China India Australia New Zealand Rest of Asia Pacific Rest of the World Middle East Brazil Argentina South Africa Egypt Major Points From Table Of Contents: Executive Summary Preface Market Trend Analysis Porters Five Force Analysis Key Developments Company Profiling About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/circulating-tumor-cells-global-market-outlook-2015-2022
Lagatie O.,Janssen Diagnostics Inc. |
Tritsmans L.,Janssen Research and Development |
Stuyver L.J.,Janssen Diagnostics Inc.
Virology Journal | Year: 2013
Polyomaviruses are a family of non-enveloped DNA viruses infecting several species, including humans, primates, birds, rodents, bats, horse, cattle, raccoon and sea lion. They typically cause asymptomatic infection and establish latency but can be reactivated under certain conditions causing severe diseases. MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in several cellular processes by binding to and inhibiting the translation of specific mRNA transcripts. In this review, we summarize the current knowledge of microRNAs involved in polyomavirus infection. We review in detail the different viral miRNAs that have been discovered and the role they play in controlling both host and viral protein expression. We also give an overview of the current understanding on how host miRNAs may function in controlling polyomavirus replication, immune evasion and pathogenesis. © 2013 Lagatie et al.; licensee BioMed Central Ltd.
Scripps Health, Janssen Diagnostics Inc. and Ortho Clinical Diagnostics Inc. | Date: 2015-05-15
Compositions, systems and methods for the diagnosing the risk of acute myocardial infarction are provided. The methods described herein relate to the use of biomarkers, such as gene expression profiles, and analytical tools for providing information to a health care provider or the patient, that is relevant to the cardiovascular health of the patient.
Van Loy T.,Janssen Diagnostics Inc. |
Thys K.,Janssen Infectious Diseases Community Of Research Excellence And Advanced Technology Create |
Tritsmans L.,Janssen Neuroscience Development |
Stuyver L.J.,Janssen Diagnostics Inc.
PLoS ONE | Year: 2013
JC virus is a human polyomavirus that infects the majority of people without apparent symptoms in healthy subjects and it is the causative agent of progressive multifocal leucoencephalopathy (PML), a disorder following lytic infection of oligodendrocytes that mainly manifests itself under immunosuppressive conditions. A hallmark for JC virus isolated from PML-brain is the presence of rearrangements in the non-coding control region (NCCR) interspersed between the early and late genes on the viral genome. Such rearrangements are believed to originate from the archetype JC virus which is shed in urine by healthy subjects and PML patients. We applied next generation sequencing to explore the non-coding control region variability in urine of healthy subjects in search for JC virus quasispecies and rearrangements reminiscent of PML. For 61 viral shedders (out of a total of 254 healthy subjects) non-coding control region DNA and VP1 (major capsid protein) coding sequences were initially obtained by Sanger sequencing. Deletions between 1 and 28 nucleotides long appeared in ∼24.5% of the NCCR sequences while insertions were only detected in ∼3.3% of the samples. 454 pyrosequencing was applied on a subset of 54 urine samples demonstrating the existence of JC virus quasispecies in four subjects (∼7.4%). Hence, our results indicate that JC virus DNA in urine is not always restricted to one unique virus variant, but can be a mixture of naturally occurring variants (quasispecies) reflecting the susceptibility of the non-coding control region for genomic rearrangements in healthy individuals. Our findings pave the way to explore the presence of viral quasispecies and the altered viral tropism that might go along with it as a potential risk factor for opportunistic secondary infections such as PML. © 2013 Van Loy et al.
Janssen Diagnostics Inc. | Date: 2014-03-14
The disclosed invention includes methods and kits for the removal of white blood cells from samples of enriched rare cells.
Janssen Diagnostics Inc. | Date: 2013-02-13
The disclosed edge-blocker oligonucleotide based AS-NEPB-PCR method amplifies allele specific DNA (or RNA) while dramatically blocking amplification of wild type (WT) DNA (or RNA). The AS-NEPB-PCR design allows ready modification of an existing PCR reaction setup with an edge-blocker oligonucleotide together with an allele specific primer complementary to the mutant sequence to achieve allele specific amplification. The method simplifies assay optimization procedures and achieved sensitivity sufficient to detect a signal present at 0.1% level with close to 100% specificity, which is useful in detecting SNP or genetic mutations. The method was used to detect three different genetic mutations in cancer, in KRAS, BRAF, and EGFR, with three different types of modified edge-blocker oligonucleotides (phosphate, inverted dT and amino-C7). It was possible to detect one copy of mutant DNA in 1000-copy of normal DNA background of a heterogeneous sample, and was far more sensitive than the other blocking method.
Janssen Diagnostics Inc. | Date: 2015-06-23
The invention relates generally to the field of the identification of DNA sequences, genes or chromosomes. Methods and composition to obtain Unique Sequence DNA probes are provided. Compositions comprises of and double stranded DNA containing Unique Sequences from which the repetitive sequences are eliminated according to the method described in this invention. The invention also relates to the preservation of cells that have been identified after immunomagnetic selection and fluorescent labeling in order to further interrogate the cells of interest. Furthermore the invention relates to genetic analysis of cells that have been identified after immunomagnetic selection and fluorescent labeling.
Janssen Diagnostics Inc. | Date: 2015-05-13
Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.
Janssen Diagnostics Inc. | Date: 2014-06-24
Circulating Endothelial Cells are isolated from patient blood and gene expression of the cells is analyzed to assess a medical condition or the tissue of origin of the cell. Kits for conducting the method are also provided.